Showing 3791-3800 of 4107 results for "".
- Phase 3 Results for Novartis' Secukinumab Reportedhttps://practicaldermatology.com/news/20140322-phase_3_results_for_novartis_secukinumab_reported/2459300/Results from the Phase III FEATURE and JUNCTURE studies show Novartis' secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011)
- FDA Approves Novartis Drug Xolair for Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20140321-fda_approves_novartis_drug_xolair_for_chronic_idiopathic_urticaria/2459302/The FDA approved Xolair (Novartis, omalizumab) for the treatment of chronic idiopathic urticaria (CIU) for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Xolair is not used to treat other forms of urticaria (
- SeroVital®–hgh AKA the "Fountain of Youth" Pillhttps://practicaldermatology.com/news/20140320-serovitalhgh_aka_the_fountain_of_youth_pill/2459306/SeroVital®–hgh is a growth hormone that the maker says can reduce wrinkles, tighten skin, decrease body fat and increase energy. Gina Daines, spokesperson for SanMedica International™ said, "Human growth hormone is no longer solely the province of male athletes. Research is revealing tha
- Launch of TrueLipids® Made with Zemea® Propanediolhttps://practicaldermatology.com/news/20140320-launch_of_truelipids_made_with_zemea_propanediol/2459307/Cheryl Lee, MD, Sensitive Skin Care, is soon launching its patent-pending line, TrueLipids® therapeutic products. TrueLipids, now made with Zemea® is designed to repair disrupted skin barriers and promote lipid production, while being cosmetically friendly to the skin. This new li
- FDA approves Impavido to treat tropical disease leishmaniasishttps://practicaldermatology.com/news/20140320-fda_approves_impavido_to_treat_tropical_disease_leishmaniasis/2459308/The US Food and Drug Administration approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is a disease caused by Leishmania, a parasite which is transmitted to humans through sand fly bites. The disease occurs primarily in people who live in the tropics and
- Pierre Fabre Obtains FDA Approval to Market Hemangeol for the Treatment of Infantile Hemangiomahttps://practicaldermatology.com/news/20140319-pierre_fabre_obtains_fda_approval_to_market_hemangeol_for_the_treatment_of_infantile_hemangioma/2459311/Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for “proliferating infantile hemangioma requiring s
- Ferndale Healthcare Announces Partnership with Colon Cancer Alliancehttps://practicaldermatology.com/news/20140318-ferndale_healthcare_announces_partnership_with_colon_cancer_awareness/2459313/Ferndale Healthcare's RectiCare® Cream, intended to resolve all discomfort from rectal and anal conditions such as hemorrhoids and anal fissures, urges colon screening for cancer before individuals reach for their brand. The brand wants to promote individuals to not rush to treat when bleeding an
- Doctors Issue New Treatment Guidelines for Skin Abscesses Caused By MRSAhttps://practicaldermatology.com/news/20140317-doctors_issue_new_treatment_guidelines_for_skin_abscesses_caused_by_mrsa/2459315/It has been more than 10 years since the clinical battle began with community-acquired methicillin-resistant Staphylococcus aureus (MRSA), and doctors are still grappling with how to diagnose, treat and prevent this virulent form of staph infection, which is immune to man
- Antares Pharma Announces LEO Pharma's Launch of Otrexup (Methotrexate) Injection for Adults with Psoriasishttps://practicaldermatology.com/news/20140311-antares_pharma_announces_leo_pharmas_launch_of_otrexup_methotrexate_injection_for_adults_with_psoriasis/2459320/Antares Pharma, Inc. announced LEO Pharma's launch of Otrexup, the first FDA-approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. "We are very pleased that
- Aquavit Pharmaceuticals Appoints David J. Goldberg as Chief Medical Officerhttps://practicaldermatology.com/news/20140305-aquavit_pharmaceuticals_appoints_david_j_goldberg_as_chief_medical_officer/2459324/Aquavit Pharmaceuticals, Inc., appointed David J. Goldberg, MD, JD as its Chief Medical Officer. Dr. Goldberg is recognized nationally and internationally for his innovative work with skin lasers, cosmetic dermatology and facial rejuvenation techniques. Prior to joining Aquavit,